A new track for antibacterial treatment: Progress and challenges of using cytomembrane-based vesicles to combat bacteria

The emergence and re-emergence of antibiotic-resistant bacteria, especially superbugs, are leading to complicated infections that are increasingly difficult to treat. Therefore, novel alternative antimicrobial therapies are urgently needed to reduce the morbidity and mortality caused by antibiotic resistance. The development of biomimetic-based therapy is expected to provide innovative means for addressing this challenging task. As a kind of novel biomaterial, cytomembrane-based vesicles (MVs) continue to receive considerable attention in antimicrobial therapy owing to their inherent biocompatibility, design flexi-bility, and remarkable ability to interact with biological molecules or the surrounding environment. These remarkable cell-like properties and their inherent interaction with pathogens, toxins, and the immune system underlie MVs-based functional protein therapy and targeted delivery to develop advanced therapeutic strategies against bacterial infection. This review provides a fundamental under-standing of the characteristics and physiological functions of cytomembrane-based vesicles, focusing on their potential to combat bacterial infections, including detoxification, immune modulation, antibiotics delivery, and physical therapy. In addition, the future possibilities and remaining challenges for clinically implementing MVs in the field of antibacterial treatment are discussed. (c) 2022 Chinese Society of Particuology and Institute of Process Engineering, Chinese Academy of Sciences. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

Automated summary

The emergence and re-emergence of antibiotic-resistant bacteria, especially superbugs, are leading to complicated infections that are increasingly difficult to treat. Therefore, novel alternative antimicrobial therapies are urgently needed to reduce the morbidity and mortality caused by antibiotic resistance.